|  | Cancer | Lymphoma

B-Cell Lymphoma: Types, Diagnosis, and Modern Treatment Breakthroughs

B-cell lymphomas are malignancies of antibody-producing B lymphocytes. They comprise about 85% of non-Hodgkin lymphomas (NHL) and include Hodgkin lymphoma (HL). Incidence: roughly 80,000 NHL and 8,500 HL cases annually in the U.S.

Major Subtypes (WHO Classification)

Aggressive (Fast-Growing)

  • Diffuse Large B-Cell Lymphoma (DLBCL): Most common NHL (~30%). Curable with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone). Subtypes: GCB vs. ABC (prognostic); double-hit (MYC+BCL2/BCL6) = high-risk.
  • High-Grade B-Cell Lymphoma (HGBL): Double/triple-hit, NOS. Intensive regimens (DA-EPOCH-R, R-CODOX-M/IVAC).
  • Burkitt Lymphoma: MYC translocation. Very aggressive; curable with dose-intensive chemo (CODOX-M/IVAC, hyper-CVAD). Endemic (malaria/EBV), sporadic, immunodeficiency-associated.
  • Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Young women, thymic origin. DA-EPOCH-R preferred (avoids mediastinal radiation).

Indolent (Slow-Growing)

  • Follicular Lymphoma (FL): Most common indolent (~20% NHL). t(14;18) BCL2. Watch-and-wait for low tumor burden; anti-CD20 ± chemo/lenalidomide for treatment. Transformation to DLBCL (~2–3%/year).
  • Marginal Zone Lymphoma (MZL): Extranodal (MALT), nodal, splenic. H. pylori+ gastric MALT → antibiotics first.
  • Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): Same disease; blood vs. nodes. BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), BCL2 inhibitor (venetoclax) ± anti-CD20. Time-limited venetoclax-based regimens emerging.
  • Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinemia: IgM paraprotein. BTK inhibitors, proteasome inhibitors, anti-CD20.

Hodgkin Lymphoma (HL)

  • Classical HL (cHL): Reed-Sternberg cells. Subtypes: nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted.
  • Nodular Lymphocyte-Predominant HL (NLPHL): "Popcorn" cells (LP cells). Indolent.
  • Curable in >85% (early) and >75% (advanced) with ABVD ± brentuximab vedotin, escalated BEACOPP, PD-1 inhibitors (relapsed).

Diagnosis and Staging

  • Excisional/incisional biopsy (core needle inadequate for architecture)
  • IHC: CD20, CD10, BCL2, BCL6, MUM1, Ki-67, MYC, Cyclin D1, CD5, CD23, CD30, CD15, PAX5, ALK
  • Flow cytometry (CLL/SLL, MCL)
  • FISH: MYC, BCL2, BCL6, CCND1, TP53
  • Staging: PET-CT (Deauville score), bone marrow biopsy (indolent, advanced aggressive), LDH, HIV, HBV, HCV

Modern Treatment Paradigms

  • Immunochemotherapy: Anti-CD20 (rituximab, obinutuzumab) + chemo backbone
  • Targeted agents: BTK inhibitors (CLL, MCL, WM, MZL), BCL2 inhibitor (venetoclax – CLL, FL), PI3Kδ inhibitors (idelalisib, copanlisib, duvelisib – toxicity concerns), EZH2 inhibitor (tazemetostat – FL, EZH2 mut)
  • Cellular therapy: CAR-T (axi-cel, tisa-cel, liso-cel, brexu-cel) – relapsed/refractory DLBCL, FL, MCL, PMBCL. Bispecifics (glofitamab, epcoritamab, mosunetuzumab) – off-the-shelf, outpatient.
  • Radiation: Consolidation (early HL, PMBCL), palliative, involved-site
  • Stem cell transplant: Autologous (consolidation aggressive, relapsed); Allogeneic (relapsed post-auto, high-risk features)

Survivorship

Long-term risks include second cancers (AML/MDS, solid tumors), cardiovascular disease, endocrine dysfunction, infertility, and psychosocial sequelae. Risk-adapted surveillance is essential.

Lymphoma - Related Articles